ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona
Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic
DNA-based therapeutics and innovative disease-modifying medicines
for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive
Officer and Chairman, will be the featured presenter at the
upcoming Harvard Investors Group forum. Mr. Riley will provide an
overview of the Company's synthetic biologics program, its
collaboration with Intrexon Corporation for pulmonary arterial
hypertension and its funded clinical trial programs at the
invitation-only dinner event on Monday evening, February 13, 2012, at The Manhattan Club in
New York City.
"Our group of qualified investors and investment professionals
within the New York City financial
and investment industries is pleased to welcome Mr. Riley to the
upcoming Harvard Investors Group dinner meeting," said John O'Dea,
Chairman of the Harvard Investors Group. "Adeona's new senior
management team will provide our invited guests with an in-depth
look at the Company's new focus on the emerging area of synthetic
DNA-based therapeutics, as well as its funded clinical programs for
multiple sclerosis, fibromyalgia and ALS."
Adeona intends to file the slide deck used at the Harvard
Investors Group forum in a Current Report on Form 8-K with the
Securities & Exchange Commission, concurrent with its
presentation on Monday, February 13,
2102.
About Harvard Investors Group
Harvard Investors Group is a private organization. Attendance is
by invitation only. Harvard Investors Group provides a forum for
public and private companies to present information about their
businesses to securities industry professionals. Harvard Investors
Group neither recommends nor solicits participation in the
presenting companies. Harvard Investors Group receives a fee for
arranging each of its meetings. Harvard Investors Group and the
meetings it hosts are in no way affiliated with Harvard University. No business solicitations of
presenting companies are permitted at the meetings. For more
information about Harvard Investors Group, please visit the website
at www.harvardinvestors.org.
About Adeona Pharmaceuticals, Inc.
Adeona is a biotechnology company focused on the development of
synthetic DNA-based therapeutics and innovative disease-modifying
medicines for serious illnesses. Adeona is developing, or has
partnered the development of, product candidates to treat pulmonary
arterial hypertension, relapses in multiple sclerosis, cognitive
dysfunction in multiple sclerosis, fibromyalgia and amyotrophic
lateral sclerosis (ALS). For more information, please visit
Adeona's website at www.adeonapharma.com.
Adeona is currently d/b/a Synthetic Biologics, Inc. (NYSE Amex:
SYN) pending stockholder approval of the name change at a Special
Meeting to be held on February 15,
2012. The proposed name change better reflects the Company's
mission and primary business focus on the emerging field of
synthetic biologics.
Synthetic Biologics is a trademark of Adeona Pharmaceuticals,
Inc.
SOURCE Adeona Pharmaceuticals, Inc.
